High-throughput Synthesis, Screening, and Bioanalysis Automated Platform for Identifying Drugs

Back to all technologies
Download as PDF
NCS: Researchers at Purdue University have developed a high-throughput platform for identifying drug candidates. The drug discovery process is expensive and time-consuming, requiring years to develop a commercial drug. This can be attributed to the manual, fragmented steps in the process. The Purdue researchers developed an automated sample-handling system that synthesizes and analyzes libraries of chemical compounds and then runs biological assays on the compounds. The system can screen 6,144 reactions in one hour at ultra-small quantities ("make-to-measure"), allowing the analysis of many reaction conditions to select the optimal conditions. The system conducts analysis via desorption electrospray ionization mass spectrometry (DESI-MS). The DESI-MS system is used to both identify compounds and analyze the results of enzymatic/receptor assays for cytotoxicity and bioactivity. For high-interest candidate compounds, Raman spectroscopy can be conducted and the results compared to predicted spectra. The researchers identified new non-addictive highly-potent opioids and new oximes (chemical warfare agent antidotes) as potential classes of compounds for analysis with this system.

Technology Validation: The researchers' system can screen 6,144 reactions in one hour and can screen cytotoxicity and bioactivity at a rate of 384 samples per hour.

-Identifies ideal reaction conditions

-Identifying and evaluating non-addictive pain medication and high-potency overdose reversal treatment
-Creating databases of synthetic opioids not yet introduced onto the streets
Mar 18, 2021
PCT-Gov. Funding

May 20, 2020
Provisional-Gov. Funding
United States
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org